phase 3 (of a clinical trial)sān qī三期clinical triallínchuáng shìyàn临床试验to confirm / to provezhèngshí证实new type / novelxīn xíng新型antihypertensive drugjiàngyā yào降压药baxdrostat (drug name)Bā shā sī tā巴沙司他therapeutic efficacyliáoxiào疗效significant / markedxiǎnzhù显著。
April 4, 2026 at 2:00 PM
New Words
News in English
Lifestyle & CulturePhase 3 Trial Shows Baxdrostat Significantly Lowers Blood Pressure in Patients Resistant to Standard Treatment
A phase 3 clinical trial in the New England Journal of Medicine shows baxdrostat, an aldosterone synthase inhibitor, significantly lowers blood pressure in resistant hypertension patients, with around 40 percent reaching healthy levels.
The latest issue of the New England Journal of Medicine published the phase 3 clinical trial results for the new antihypertensive drug baxdrostat. The trial enrolled 794 patients with treatment-resistant or uncontrolled hypertension, randomly assigned to receive 1 milligram, 2 milligrams of baxdrostat, or placebo for a 12-week course. Results showed that patients taking 1 milligram had average systolic blood pressure decrease of 14.5 mmHg, and those taking 2 milligrams decreased 15.7 mmHg, both significantly better than the placebo group's 5.8 mmHg. Notably, approximately 40% of treated patients' blood pressure recovered to healthy levels, far exceeding the placebo group's less than 20% proportion. Baxdrostat is an aldosterone synthase inhibitor that lowers blood pressure by inhibiting adrenal secretion of the aldosterone hormone, with a mechanism completely different from existing first-line antihypertensive drugs. Researchers noted this target is particularly effective for patients whose hypertension is caused by excessive aldosterone secretion, a considerable proportion of the treatment-resistant hypertension population. Regarding safety, a small number of participants developed hyperkalemia, requiring clinical monitoring. The US FDA has placed the drug in priority review, with approval targeted for the second quarter of 2026. Given the global hypertension patient population exceeds one billion, with considerable treatment-resistant cases, these trial results are viewed by the medical community as an important breakthrough.
More in Lifestyle & Culture
CanadaJiānádà加拿大poetshīrén诗人Anne Carson (Canadian poet)Ānnī Kǎsēn安妮·卡森to win / to be honored withrónghuò荣获20262026 nián2026年NobelNuòbèiěr诺贝尔Prize in Literaturewénxué jiǎng文学奖。
Canadian Poet Anne Carson Wins 2026 Nobel Prize in Literature
threesān wèi三位scientistskēxué jiā科学家for / because ofyīn因pioneeringkāichuàng开创optogeneticsguāng yíchuán xué光遗传学technologyjìshù技术jointlygòngtóng共同to be awardedrónghuò荣获20262026 nián2026年NobelNuòbèiěr诺贝尔Physiologyshēnglǐ xué生理学orhuò或Medicine Prizeyīxué jiǎng医学奖。
Three Scientists Win 2026 Nobel Prize in Medicine for Pioneering Optogenetics Technology
Molchanov (champion freediver)Mò ěr chá nuò fū莫尔查诺夫with / at (a score of)yǐ以137 meters137 mǐ137米to set / to establishchuàng创constant weighthéngzhòng恒重freedivingzìyóu qiánshuǐ自由潜水mennánzǐ男子world recordshìjiè jìlù世界纪录。
Alexey Molchanov Sets Freediving World Record With 137-Meter Dive at World Championships in Limassol
CanadaJiā ná dà加拿大author / writerzuò jiā作家Anne Carson (Canadian author)Ān nī Kǎ sēn安妮·卡森to be honored with / to winróng huò荣获the year 20262026 nián2026年NobelNuò bèi ěr诺贝尔Prize in Literaturewén xué jiǎng文学奖。
Canadian Author Anne Carson Wins 2026 Nobel Prize in Literature